Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of bermekimab in adults with moderate to severe atopic dermatitis
2020-002587-31Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bermekimab in atopic dermatitis (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of participants achieving EASI-75. Started Dec 2020; status: completed.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-002587-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002587-31.